The vaccine targets the pleasure inducing sensations owing to nicotine addiction, and impairs them. This results in obliterating the urge to smoke. The vaccine is capable of generating antibodies that will hold on to the nicotine molecules and stop them from getting anywhere close to the brain.
Dr Frank Vocci, director of the US National Institute on Drug Abuse's division of pharmacotherapies expressed hope that a quick review of the product is expected after which an FDA approval will see the product through in the market. He said "That means they will do a rapid review and get back to the sponsor within so many months. They've put a spotlight on it and really tried to move it along, because it would be a unique product."
The only catch is that the antibodies which a single dose of Nic Vax generates will get depleted in a month. This will necessitate the need for multi-doses. A parallel clinical trial for multi-shot response is being tested on 300 people after which the vaccine will await FDA approval.
A positive stride in smoking cessation initiatives.